

April 2, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
Scrip Code: 500135

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G,
Bandra-Kurla Complex, Bandra (E), Mumbai - 400051
Trading Symbol: EPL

Sub. : Newspaper publication with respect to special window for transfer and dematerialisation of physical shares of EPL Limited ("Company")

Dear Sir/ Madam,

We wish to inform you that the Company has, in terms of the provisions of the Circular dated January 30, 2026, bearing reference no. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026, issued by the Securities and Exchange Board of India, published newspaper advertisement(s) with respect to opening of a special window, for a period of one year i.e. from February 5, 2026 till February 4, 2027, to facilitate transfer and dematerialisation of physical shares of the Company, which were sold/purchased prior to April 1, 2019.

The copy(ies) of such newspaper advertisement(s) published in following newspapers are enclosed herewith for reference:

- Business Standard, All India Edition(s) (in English) (*while the advertisement is published in all editions of Business Standard, in India, only one of them published in Business Standard, Mumbai Edition, is enclosed herewith for reference*);
- Navshakti, Mumbai Edition (in Marathi).

The above newspaper advertisement(s) are also available on the website(s) of the Company at www.eplglobal.com.

This is for your information and records.

Thanking you.

Yours faithfully,
For **EPL Limited**

Onkar Ghangurde
Head - Legal, Company Secretary & Compliance Officer
Encl.: As above

The weight of claims

As India's weight management market expands, the risk of misleading, surrogate ads may also increase

ANUSHKA BHARDWAJ
New Delhi, 31 March

India's buzzing weight-management market is busier than ever. After tea, powders, supplements and pills, weight-loss injections are the hottest thing. With semaglutide, the active ingredient in slimming drugs, having gone off-patent on March 20 in India, over a dozen domestic firms are jostling to launch affordable versions of the drug.

That's not surprising: According to market research firm IMARC, India's weight-management market was valued at \$2.4 bn in 2025 and demand for products is growing. That's because nearly one in every four adults in the country is obese. And according to the World Obesity Atlas 2026, India now ranks second in terms of overweight and obese children. Another reason is ads that make dubious claims to slimming. The advertising industry is walking a tightrope between promoting awareness and making exaggerated claims.

"Writing for weight-loss (ads) in India sits at the intersection of aspiration, insecurity, regulation, and cultural truth. It's one of the most sensitive categories to handle," said Ujjwal Anand, managing partner - North, Dentus Creative Webchutney, a Mumbai-based creative agency.

A week before semaglutide's patent expiry, the Central Drugs Standard Control Organization issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law.

Alarm bells

"It has been brought to the notice that certain pharmaceutical companies may be engaging in direct or indirect (surrogate) promotional activities, including disease awareness campaigns, digital media outreach, and other communications, relating to GLP-1 receptor agonists and similar prescription drugs indicated for

obesity and metabolic disorders," CDSCO noted in an advisory issued on March 11. GLP-1 receptor agonists are a class of medicines used to treat diabetes and obesity.

Even before the formal advisory, medical professionals were warning against the influence of advertisements for such products. "In just a year or so these injections have taken over the market as some 'magical drug' and the information about their usage is still limited among the general public. No advertisement says that it requires strict diet, exercise, and monitoring," said Dr Anil Peters, a Delhi-based bariatric surgeon. "Nearly 50 per cent of the patients, who should ideally opt for surgeries — due to extreme obesity — are asking us to prescribe these drugs."

Promotion of prescription drugs is prohibited under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. While conventional media like print and television refrain from making specific claims about weight loss, digital and influencer marketing platforms often exploit what is described as a grey area.

"Influencing happens to the extent that people who have gone through surgery are making videos saying that they used XY or Z injections for the transformation. This is not direct advertising but these are fraudulent claims and can influence people," said Peters.

The side-effects of unapproved consumption of these drugs could start with gastroenteritis, including vomiting, nausea and abdominal pain, and could turn severe in some cases, impacting vital organs like the pancreas and eyes.

Globally, Novo Nordisk — the makers of popular weight-loss injections Ozempic and Wegovy — is fighting more than 1,800 lawsuits filed by users who developed stomach paralysis, vomiting and even loss of vision, allegedly as a side-effect. The potential hit could cross \$2 billion.

"Sometimes, the prescription

is made by doctors who are not even qualified to handle obesity or diabetes cases," Peters said.

The big claim story
While these injections are still new in the Indian market, over-the-counter products promoting weight loss have long been around, as have concerns over false claims.


According to the Advertising Standards Council of India (Asci)'s half-yearly report for April-September 2025, 81.6 per cent of the 332 cases it dealt with in the healthcare sector were found to violate the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Healthcare remains the third-most violative sector in advertising after betting and personal care, it said.

"Non-prescription products are often marketed as food, herbal or wellness products but sometimes may make therapeutic or disease-related claims," said Manisha Kapoor, chief executive officer and secretary general of Asci.

In August 2025, the Central Consumer Protection Authority (CCPA) fined wellness firm VLCC ₹3 lakh for publishing misleading advertisements regarding treatments through the use of US Food and Drug Agency-approved "CoolSonic" fat-freezing procedure/machine. CCPA also fined Mumbai-based beauty clinic Kaya Ltd for making similar claims of weight loss.

Interestingly, the rise of digital advertising means the cost and



speed of bringing down a misleading ad now is less. If a claim is proven to be misleading, the brand can remove the post quickly.

"During print and television, this was not as easy, which is why more neutral language like 'weight management' was used instead of 'guaranteed results,'" said Ashish Chakravarty, partner

India's GLP-1 agonists weight-loss drug market

■ 2024 market revenue: \$82.2 mn
■ 2030 market revenue (estimate): \$352.3 mn
■ Growth rate: 24.6% (from 2025 to 2030)
■ Largest segment: Semaglutide
■ Fastest-growing segment: Tirzepatide

India's weight-loss supplements market

■ 2024 market revenue: \$1,367.2 mn
■ 2030 market revenue (estimate): \$3,830.2 mn
■ Growth rate: 18.7% (from 2024 to 2030)
■ Largest segment: Powder
■ Fastest-growing segment: Pills

Source: Grand View Horizon

has prompted advertisers to try and navigate their way around.

"Writing weight-loss advertising is not just copywriting — it's behavioural science plus regulation and storytelling," said Anand. Ad agencies, he said, have to do a balancing act between authenticity and exaggeration by dramatizing the outcome, but not falsifying the claim — using aspiration without promising miracles. "Today, smarter brands are moving from 'lose 10 kg in 10 days' to sustainable, science-backed transformation," Anand said. Recently, weight-loss drug-maker Eli Lilly put out an ad that touched upon the sensitivity of the topic by showing how a person with obesity accepts the criticism without understanding that it is a disease that requires medical intervention.

"They are asking people to consider obesity as a disease and not just a lifestyle problem," Anand said.

Gatekeepers at work

The claims and complaints have kept regulators like CCPA and Asci on their toes. "When complaints are received and adequate substantiation for claims made is not provided, Asci typically asks the advertiser to modify or withdraw the advertisement," said Kapoor.

However, in some cases, if the ads are thought to violate statutory provisions such as the Drugs and Magic Remedies (Objectionable Advertisements) Act, Asci refers them to the relevant regula-

tor, including the Ministry of AYUSH or other concerned departments. To be sure, attempts to deal with false claims can start as early as the product going for clearance to the Food Safety and Standards Authority of India (FSSAI).

"For any nutraceutical product, the process starts with a team of 9 experts, a few FSSAI members and a chair. All claims and aspects of the product are studied before having another meeting with a specialist like an endocrinologist or diabetologist — depending on the claim made," said a nutritional scientist at FSSAI. The said next step includes sending all queries to the makers who have to respond to a team of 21 experts and five external members. The final steps include sending the sample to the health secretariat and putting the draft on the website for comments. In most cases, it is a rigorous process of 10-12 steps. "She said the number of weight-loss products coming for clearance has seen a large spike over the years. Advertisers also claim to take on some of the responsibility — they say there are discussions with the brand before any claim is added to the ad script.

"We do ask about the clinical trials, ingredient level proof, advisory board, etc. This becomes the claim playground — what is legally and scientifically defensible," said Anand.

The ultimate responsibility of the content lies with the advertiser, he said, admitting that a credible agency would not blindly parrot a claim. "They will push back on unrealistic claims, recommend defensible language and insist on disclaimers wherever required."

According to experts, there is a risk-and-impact trade-off where the honest way to pick dull but safe lines — like 'product supports weight management' instead of the 'transform your body in weeks'.

The growth of the weight loss product industry means the advertising sector is a collaborator. With India preparing to address obesity-related health challenges amid a range of new products entering the market, the number of misleading claims and surrogate advertisements is expected to rise. And that in turn will require regulators to keep a hawk eye on dubious claims.

NEW & RENEWABLE ENERGY DEVELOPMENT CORPORATION OF A.P. LTD
(A State Government Company)
Regd. Office: 917/24/501, River Oaks Apartments,
CSR KalyanaMandiram Road, Taseerabad, Guntur, Telangana-522475/51/52/53/54
Email: info@nredcap.in, we@nredcap.in, Website: www.nredcap.in
Ref: NREDCAP/W/E/A and TPT Clusters-2025-26, Date: 31.03.2026

NOTICE INVITING TENDERS
New & Renewable Energy Development Corporation of Andhra Pradesh Limited (NREDCAP) invites e-tenders for selection of Developers to establish 15.00 MW Municipal Solid Waste (MSW) based Waste to Energy Plant at Vijayawada cluster and 12.00 MW Municipal Solid Waste (MSW) based Waste to Energy Plant at Tirupati cluster, Andhra Pradesh on PPP basis. For information, please visit website: <https://tenders.ap.nredcap.gov.in> or NREDCAP website: www.nredcap.in. Web site details and tender documents will be uploaded on 01-04-2026.
Sd/-VC & Managing Director

THE GREAT EASTERN SHIPPING COMPANY LIMITED
CIN: L35110MH1945FL000472
Registered Office: Ocean House, 13/14A, Dr. Ambe Bessard Road, Worli, Mumbai - 400018.
Tel No.: +91 (22) 66613000/24922100; Fax: +91 (22) 24925900
Email: shares@greatship.com; Website: www.greatship.com

NOTICE OF POSTAL BALLOT
Members are hereby informed that pursuant to Sections 108, 110 and other applicable provisions of the Companies Act, 2013 ("the Act") read with the Companies (Management & Administration) Rules, 2014 and in compliance with the circulars dated April 08, 2020 and April 13, 2020 issued by the Ministry of Corporate Affairs ("MCA") and other applicable circulars issued by MCA and the Securities and Exchange Board of India ("SEBI"), the approval of the Members is sought by way of Postal Ballot for:

1. Re- appointment of Mrs. Bhavna Doshi as an Independent Director of the Company for a second term from May 11, 2026 to October 25, 2030.

The Notice of Postal Ballot has been sent to the Members of the Company whose email addresses are registered with the Company/Depository Participant(s) by way of email on March 31, 2026. The same is also available at the Company's website: www.greatship.com and on the websites of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and on the website of National Securities Depository Limited ("NSDL") (www.evoting.nsdl.com).

In accordance with the circulars issued by MCA, physical copies of the Notice, Postal Ballot forms and pre-paid Business Reply Envelopes are not being sent to Members for this Postal Ballot. The Board of Directors of the Company has appointed Ms. Ashwini Inamdar, former lawyer, Ms. Alifya Sapatwala, Partners, Mehta & Mehta, Company Secretaries, as Scrutinizers for conducting the Postal Ballot and remote e-voting process in a fair and transparent manner.

The Company has also engaged the services of NSDL for providing remote e-voting facility to the Members. Members are requested to provide their address or dissent through remote e-voting only.

Members who are individuals holding shares in demat mode may cast their votes through e-voting through the website of NSDL/CDLSD/Depository Participants. Other Members may cast their votes through e-mail e-voting at https://www.evoting.nsdl.com.

Instructions pertaining to Remote e-voting
The remote e-voting period commences at 09.00 a.m. on Wednesday, April 01, 2026 and ends at 05.00 p.m. on Thursday, April 30, 2026. Remote e-voting will not be allowed beyond the said date and time and the remote e-voting module will be disabled by NSDL upon expiry of the aforesaid period. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently or cast the vote again. A Member's voting rights shall be in proportion to his/her share of the paid-up equity share capital of the Company as on Wednesday, March 25, 2026 ("cut-off date"). A person whose name is recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories as on the 'cut-off date' only shall be entitled to cast their votes by remote e-voting. A person who is not a Member as on the cut-off date should treat this Notice for information purposes only.

Manner of registering/updates e-mail addresses to receive the Notice of Postal Ballot:
Members whose email IDs are not registered with the Company/Depository Participants and consequently the Notice of Postal Ballot and remote e-voting instructions cannot be serviced, can send an e-mail request at the email evoting@nsdl.com along with following documents:

- In case of shares held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), self-attested scanned copy of PAN and Aadhar Card.
- In case of shares held in demat mode, please provide DPID - CLID, Name, client master or copy of consolidated account statement, self-attested scanned copy of PAN and Aadhar Card.

Manner of registering/updates KYC details:
SEBI, vide its Circular dated November 03, 2021 (as amended from time to time), has mandated registration of PAN, postal address, email address, mobile number, bank account details, specimen signature and non-resident by holders of physical securities. Members holding shares in physical form are requested to submit the necessary details by sending a duly filled and signed Form ISR-1, ISR-2, ISR-3/SH-13 which may be applicable to the Company or its Registrar and Share Transfer Agent (RTA), i.e. KFin Technologies Limited ("KFinTech"). Members, holding shares in electronic form, are requested to register/update their KYC details with respective Depository Participants.

In case of any queries/grievances, the Members may refer the Frequently Asked Questions (FAQs) on Members and e-voting User Manual available at the 'download' section of www.evoting.nsdl.com or call on: 022-48867000 or send a request to Ms. Pallavi Mhatre, Asst. Vice President, NSDL at evoting@nsdl.com. Members are also requested to note the following contact details for addressing remote e-voting grievances:

Ms. Pallavi Mhatre
Asst. Vice President
National Securities Depository Limited
3rd Floor, Naman Chamber,
Plot C-32, G-Block, Bandra Kurla Complex,
Bandra East, Mumbai - 400 051
Contact No.: 9769990397
Email ID: pallavi@nsdl.com

The results of the Postal Ballot will be announced on or before Sunday, May 03, 2026, at the Registered Office of the Company. The said results would be displayed at the Registered Office of the Company. The said results would also be intimated to the National Stock Exchange of India Limited and BSE Limited where the shares of the Company are listed. Additionally, the results will also be uploaded on the Company's website - www.greatship.com and on the website of NSDL - www.evoting.nsdl.com

For The Great Eastern Shipping Company Limited
Place : Mumbai
Date : 31.03.2026

ASGARD ALCOBEY LIMITED
(Formerly known as Banganga Paper Industries Limited) ("AAL" / "TARGET COMPANY" / "TC")
(Corporate Identification No. L11010MH1984PLC033082)
Registered Office: Sr. No. 185, Gavalwadi Road, Ashewadi, Ramsej, Maharashtra - 422003, India
Phone No.: +91-8974948035; Email ID: info@asgardalcobey.com; Website: www.asgardalcobey.com

Recommendations of the Committee of Independent Directors (CID) on the Offer to the Shareholders of Asgard Alcobey Limited (Formerly Known as Banganga Paper Industries Limited) ("AAL" or the "Target Company") under regulation 26 (7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereunder ("SEBI (SAST) Regulations")

Date	30.03.2026
Name of the Target Company	Asgard Alcobey Limited (Formerly Known as Banganga Paper Industries Limited)
Details of the Offer pertaining to Target Company	Open Offer to acquire up to 9,17,41,759 Equity Shares of face value of Rs. 1/- each representing 26.00% of the paid-up equity and voting share capital of the Target Company, to be acquired by the Acquirers, at a price of Rs. 1.45/- per equity share payable in cash in terms of Regulation 31(1) and Regulation 40f of the SEBI (SAST) Regulations, 2011.
Name(s) of the Acquirers and with the Acquirers	Ponak Jain (Acquirer-1); Sarla Jain (Acquirer-2); Priyanka Jain (Acquirer-3); K K Impex & Trading Private Limited (Acquirer-4); Karan Jain (PAC-1); Kartishma Rohit Jain (PAC-2) and Radhika Karan Jain (PAC-3)
Name of the Manager to the offer	Navigant Corporate Advisors Limited
Members of the Committee of Independent Directors ("CID")	Chairman: Mr. Mundrath Ravindranathan Member: Mr. M S Venkatesh Babu Member: Mr. Keshava Lakshminarayana Patkar
IDC Member's relationship with the Target Company (Director, Equity shares owned, any other contract/relationship), if any	IDC Members are the Independent Directors of the Target Company. Neither Chairman nor Member of IDC holds any equity shares in the Target Company. (None of them have entered into any other contract or have other relationship with the Target Company.)
Trading in the Equity Shares/other securities of the Target Company by IDC Members	No trading has been done by the IDC Members in the equity shares/ other securities of the Target Company.
IDC Member's relationship with the Acquirers and PAC (Director, Equity shares owned, any other contract/relationship), if any.	None of the IDC Members have any relationship with the Acquirers and PAC.
Trading in the Equity Shares/other securities of the acquirers by IDC Members	Not Applicable
Recommendation on the Offer or, as to whether the offer, is or is not, fair and reasonable	The IDC Members believe that the Offer and take informed decision in the matter. The shareholders should independently evaluate the Offer and take informed decision in the matter.
Summary of reasons for recommendation	IDC recommends acceptance of the Offer made by the Acquirers as the Offer price of Rs. 1.45/- per fully paid-up equity share is fair and reasonable based on the following reasons: 1. The Offer price appears to be reasonable considering net profitability of the Company. 2. The Offer price of Rs. 1.45/- per fully paid-up equity share offered by the Acquirers is equal to price paid by Acquirers for the preferential allotment and higher than the price paid to sellers for acquisition of shares under share purchase agreement. 3. The equity shares of the Target Company are infrequently traded shares within the meaning of explanation provided in Regulation 2(i) of SEBI (SAST) Regulations, 2011. 4. The Offer price of Rs. 1.45/- per fully paid-up equity share offered by the Acquirers is more than fair value of equity share of the Target Company which is Rs. 1.37/- (Rupees One and Paise Thirty-Seven Only) as certified by CA Amit Maloo, Independent Valuer (Membership No. 074898), Chartered Accountants, Registered Valuer - Securities or Financial Assets, having their office situated at Office No. 305, 3 rd Floor, Aditya Heritage, Mindspace, Mahavir Nagar, Kandivli West, Mumbai - 400064 and Registered Address at B 1205, Eka Terraces, Mahavir Nagar, Kandivli West, Mumbai - 400067. Tel. No: +91 9832697989. Email: amitmaloo@gmail.com ; amit@collab Advisors.com vide valuation certificate dated December 17, 2025 (UDIN: 25078498MJA250151)
Keeping in view above facts IDC is of opinion that Offer price is fair and reasonable and is in accordance with the relevant regulations prescribed in the Takeover Code and prima facie appear to be justified.	
Details of Independent Advisors, if any.	None
Any other matter to be highlighted, if any.	None

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations, 2011 and subsequent amendments used in this announcement, but not defined, shall have the same meaning assigned to them in the DP, PDS and LOF.

For Asgard Alcobey Limited (Formerly Known as Banganga Paper Industries Limited)
Sd/-
Mr. Mundrath Ravindranathan
Chairman - Committee of Independent Directors
DIN: 03406894

Place: Nashik
Date: 30.03.2026

EPL Limited
CIN: L74950MH1982PL028947
Registered Office: P.O. Vasod, Taluka Gadhukur,
Thane 421604, Maharashtra, Tel.: +91 96333397/9882
Corporate Office: Top Floor, Times Tower, Kamala City,
Gandhinagar, Lower Parel, Mumbai - 400 013.
Tel.: +91 22 2481 9000/9200; Fax: +91 22 24863137
E-mail: investor@epgltd.com; www.epgltd.com

SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SHARES OF EPL LIMITED

NOTICE is hereby given that, in terms of the provisions of the circular bearing reference no. HO/38/13/11(2)2026-MRSD-POD/13750/2026 dated January 30, 2026, issued by the Securities and Exchange Board of India (SEBI) ("SEBI Circular"), a Special Window has been opened for a period of one month, from February 5, 2026 till February 4, 2027 ("Special Window"), to facilitate transfer and dematerialisation (demat) of physical shares of the Company which were sold/ purchased prior to April 1, 2019.

The Shareholders are requested to refer below table, to understand which transfer requests shall be considered as valid requests, during the Special Window:

Execution Date of Transfer Deed	Lodged for transfer before April 1, 2019?	Original Security Certificate Available?	Eligible to lodge in the current window?
Before April 1, 2019	No	Yes	✓
	(It is fresh lodgement)	Yes	✓
	Yes (It was rejected/ returned earlier)	Yes	✓
	No	No	✗
	No	No	✗

The Shareholders are also requested to note that only those request(s) which are accompanied by original share certificate(s) along with transfer deed(s) and other mandatory supporting documents as laid down in the SEBI Circular, will be considered under the Special Window.

Accordingly, the Shareholders and such other persons, whose transfer requests were rejected/ returned/ not attended to/ not lodged, are requested to avail the benefit of this opportunity and get in touch with the Company's Registrar and Transfer Agent viz. Bighshare Services Private Limited ("RTA"), at the below mentioned address, for submission of necessary documents and completion of necessary formalities.

Bighshare Services Pvt. Ltd.
Unit: EPL Limited; Address: Office No. 56-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093; Tel.: 022-62638200/222/223;
Email: investor@bighshareonline.com

For more information in this regard, the concerned shareholders may get in touch with the Company at legal.secretariat@epgltd.com / RTA at investor@bighshareonline.com.

For EPL Limited
Sd/-
Onkar Ghangurde
Head - Legal, Company Secretary & Compliance Officer
Place: Mumbai
Date: March 31, 2026

ICSI Membership No.: A30636

